Takeda Pharmaceutical Co Ltd (4502.T) Quote| Reuters.com
Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,440JPY
29 Jun 2016
Change (% chg)

¥97 (+2.23%)
Prev Close
¥4,343
Open
¥4,343
Day's High
¥4,470
Day's Low
¥4,340
Volume
2,405,600
Avg. Vol
2,682,952
52-wk High
¥6,609
52-wk Low
¥4,098

4502.T

Chart for 4502.T

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.74
Market Cap(Mil.): ¥3,432,404.00
Shares Outstanding(Mil.): 790.33
Dividend: 90.00
Yield (%): 4.14

Financials

  4502.T Industry Sector
P/E (TTM): 42.95 33.67 34.69
EPS (TTM): 101.11 -- --
ROI: 2.73 14.91 14.13
ROE: 3.92 15.99 15.35

Hikma seeks dismissal of Takeda's bid to block gout drug sales

Hikma Pharmaceuticals PLC is asking a federal appeals court to reject a bid by rival Takeda Pharmaceutical Co to halt sales of Hikma's gout drug Mitigare, arguing that the challenge is moot after Hikma won a separate patent case last month.

Jun 09 2016

BRIEF-Takeda, Roivant Sciences launch Myovant Sciences to develop therapeutics for women's health, prostate cancer

* Roivant Sciences and Takeda launch Myovant Sciences to develop therapeutics for women's health and prostate cancer

Jun 06 2016

BRIEF-Takeda Pharmaceutical Co Ltd receives positive CHMP opinion for ADCETRIS

* Takeda receives positive CHMP opinion for ADCETRIS as consolidation treatment in post-transplant hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 27 2016

Valeant rejected joint takeover bid from Takeda, TPG in spring: source

Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP [TPG.UL] this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

May 26 2016

UPDATE 2-Valeant rejected joint takeover bid from Takeda, TPG in spring - source

May 26 Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

May 26 2016

BRIEF-Valeant received joint takeover approach from Takeda, TPG before Joseph Papa became CEO - source

* Valeant received joint takeover approach from Takeda, TPG a few weeks before Joseph Papa became CEO - Source Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 26 2016

Valeant rejected joint takeover bid from Takeda, TPG in spring-WSJ

May 26 Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, the Wall Street Journal reported, citing people familiar with the matter.

May 26 2016

BRIEF-Valeant approached by earlier rejected Takeda, TPG for takeover-CNBC

* Valeant received joint takeover approach from Takeda, TPG that it rejected this spring before hiring new CEO - CNBC, citing DJ

May 26 2016

Hikma wins dismissal of Takeda patent lawsuit over gout drug

A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co's gout drug Colcrys, dismissing a patent lawsuit Takeda filed in an effort to keep the drug off the market.

May 20 2016

Gates Foundation backs Takeda polio vaccine with $38 million grant

LONDON Japan's Takeda Pharmaceuticals is to get $38 million from the Bill & Melinda Gates Foundation to develop a crucial, low-cost polio vaccine for use in developing countries.

May 08 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$169.00
Provider : Wright Reports
$169.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.